J&J COVID-19 vaccine benefits ‘far outweigh’ risks, CDC panel says after reports of Guillain-Barré syndrome
Fox News
An advisory panel to the Centers for Disease Control and Prevention (CDC) said the benefits of COVID-19 vaccines “far outweigh” potential risks amid an ongoing review of reports of a rare nerve disorder in a small fraction of J&J jab recipients.
Dr. Nicola Klein with the Kaiser Permanente Vaccine Study Center noted eight confirmed cases of GBS following J&J vaccination amid a backdrop of over 345,000 doses administered, per data collected through the Vaccine Safety Datalink. Nearly all confirmed cases occurred within 21 days of vaccination and involved adults aged 18-64. Researchers noted a reporting rate of 8.1 GBS cases per million J&J doses administered, versus 1.1 such cases following mRNA vaccination, compared to approximately 1.6 expected cases of GBS per million doses administered, per data collected through a national surveillance system, VAERS.More Related News